Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.01 USD | -2.40% | +0.23% | -39.63% |
Apr. 26 | UBS Adjusts Teladoc Price Target to $16 From $20, Maintains Neutral Rating | MT |
Apr. 26 | Oppenheimer Cuts Teladoc's Price Target to $21 From $26, Maintains Outperform Rating | MT |
Financials (USD)
Sales 2024 * | 2.66B | Sales 2025 * | 2.76B | Capitalization | 2.26B |
---|---|---|---|---|---|
Net income 2024 * | -174M | Net income 2025 * | -113M | EV / Sales 2024 * | 0.95 x |
Net Debt 2024 * | 279M | Net Debt 2025 * | 70.17M | EV / Sales 2025 * | 0.84 x |
P/E ratio 2024 * |
-12.5
x | P/E ratio 2025 * |
-20.1
x | Employees | 5,208 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
Latest transcript on Teladoc Health, Inc.
1 day | -2.40% | ||
1 week | -2.18% | ||
Current month | -13.84% | ||
1 month | -14.80% | ||
3 months | -36.81% | ||
6 months | -16.44% | ||
Current year | -39.63% |
Managers | Title | Age | Since |
---|---|---|---|
Mala Murthy
CEO | Chief Executive Officer | 60 | 19-06-23 |
Jeff Nadler
CTO | Chief Tech/Sci/R&D Officer | - | 11-01-31 |
Nikolaos Nanis
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David Snow
CHM | Chairman | 69 | 14-01-31 |
Sandra Fenwick
BRD | Director/Board Member | 73 | 20-11-18 |
David Shedlarz
BRD | Director/Board Member | 75 | 16-09-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.31% | 1 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 13.01 | -2.40% | 7,696,741 |
24-04-25 | 13.33 | -2.91% | 6,876,486 |
24-04-24 | 13.73 | -0.07% | 8,062,783 |
24-04-23 | 13.74 | +3.31% | 4,003,055 |
24-04-22 | 13.3 | +2.47% | 4,223,074 |
Delayed Quote Nyse, April 26, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.63% | 2.26B | |
+40.45% | 2.63B | |
+22.83% | 520M | |
+42.77% | 467M | |
-64.56% | 160M | |
-31.65% | 87.05M |
- Stock Market
- Equities
- TDOC Stock